311 related articles for article (PubMed ID: 26517361)
21. Difference in TB10.4 T-cell epitope recognition following immunization with recombinant TB10.4, BCG or infection with Mycobacterium tuberculosis.
Billeskov R; Grandal MV; Poulsen C; Christensen JP; Winther N; Vingsbo-Lundberg C; Hoang TT; van Deurs B; Song YH; Aagaard C; Andersen P; Dietrich J
Eur J Immunol; 2010 May; 40(5):1342-54. PubMed ID: 20186878
[TBL] [Abstract][Full Text] [Related]
22. Update on the development of TB Vaccines.
Zenteno-Cuevas R
Curr Pharm Biotechnol; 2013; 14(11):940-6. PubMed ID: 24372249
[TBL] [Abstract][Full Text] [Related]
23. Current status of new tuberculosis vaccine in children.
Pang Y; Zhao A; Cohen C; Kang W; Lu J; Wang G; Zhao Y; Zheng S
Hum Vaccin Immunother; 2016 Apr; 12(4):960-70. PubMed ID: 27002369
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms of M. tuberculosis Immune Evasion as Challenges to TB Vaccine Design.
Ernst JD
Cell Host Microbe; 2018 Jul; 24(1):34-42. PubMed ID: 30001523
[TBL] [Abstract][Full Text] [Related]
25. Advances in tuberculosis vaccine strategies.
Skeiky YA; Sadoff JC
Nat Rev Microbiol; 2006 Jun; 4(6):469-76. PubMed ID: 16710326
[TBL] [Abstract][Full Text] [Related]
26. The in vivo expressed Mycobacterium tuberculosis (IVE-TB) antigen Rv2034 induces CD4⁺ T-cells that protect against pulmonary infection in HLA-DR transgenic mice and guinea pigs.
Commandeur S; van den Eeden SJ; Dijkman K; Clark SO; van Meijgaarden KE; Wilson L; Franken KL; Williams A; Christensen D; Ottenhoff TH; Geluk A
Vaccine; 2014 Jun; 32(29):3580-8. PubMed ID: 24837764
[TBL] [Abstract][Full Text] [Related]
27. Challenges and solutions for a rational vaccine design for TB-endemic regions.
Gowthaman U; Mushtaq K; Tan AC; Rai PK; Jackson DC; Agrewala JN
Crit Rev Microbiol; 2015; 41(3):389-98. PubMed ID: 24495096
[TBL] [Abstract][Full Text] [Related]
28. Targeting dendritic cells to accelerate T-cell activation overcomes a bottleneck in tuberculosis vaccine efficacy.
Griffiths KL; Ahmed M; Das S; Gopal R; Horne W; Connell TD; Moynihan KD; Kolls JK; Irvine DJ; Artyomov MN; Rangel-Moreno J; Khader SA
Nat Commun; 2016 Dec; 7():13894. PubMed ID: 28004802
[TBL] [Abstract][Full Text] [Related]
29. Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials.
McShane H; Pathan AA; Sander CR; Goonetilleke NP; Fletcher HA; Hill AV
Tuberculosis (Edinb); 2005; 85(1-2):47-52. PubMed ID: 15687027
[TBL] [Abstract][Full Text] [Related]
30. Lipidated promiscuous peptides vaccine for tuberculosis-endemic regions.
Gowthaman U; Rai PK; Khan N; Jackson DC; Agrewala JN
Trends Mol Med; 2012 Oct; 18(10):607-14. PubMed ID: 22939171
[TBL] [Abstract][Full Text] [Related]
31. Novel vaccine candidates against Mycobacterium tuberculosis.
Khoshnood S; Heidary M; Haeili M; Drancourt M; Darban-Sarokhalil D; Nasiri MJ; Lohrasbi V
Int J Biol Macromol; 2018 Dec; 120(Pt A):180-188. PubMed ID: 30098365
[TBL] [Abstract][Full Text] [Related]
32. Future vaccination strategies against tuberculosis: thinking outside the box.
Kaufmann SH
Immunity; 2010 Oct; 33(4):567-77. PubMed ID: 21029966
[TBL] [Abstract][Full Text] [Related]
33.
Ryndak MB; Laal S
Front Cell Infect Microbiol; 2019; 9():299. PubMed ID: 31497538
[TBL] [Abstract][Full Text] [Related]
34. Mycobacterium tuberculosis infection and vaccine development.
Tang J; Yam WC; Chen Z
Tuberculosis (Edinb); 2016 May; 98():30-41. PubMed ID: 27156616
[TBL] [Abstract][Full Text] [Related]
35. [Immunology of tuberculosis: impact on the development of novel vaccines].
Ulrichs T; Kaufmann SH
Internist (Berl); 2003 Nov; 44(11):1374-84. PubMed ID: 14689073
[TBL] [Abstract][Full Text] [Related]
36. Repeated Aerosolized-Boosting with Gamma-Irradiated Mycobacterium bovis BCG Confers Improved Pulmonary Protection against the Hypervirulent Mycobacterium tuberculosis Strain HN878 in Mice.
Cha SB; Kim WS; Kim JS; Kim H; Kwon KW; Han SJ; Eum SY; Cho SN; Shin SJ
PLoS One; 2015; 10(10):e0141577. PubMed ID: 26509812
[TBL] [Abstract][Full Text] [Related]
37. New approaches to TB vaccination.
Xing Z; Jeyanathan M; Smaill F
Chest; 2014 Sep; 146(3):804-812. PubMed ID: 25180725
[TBL] [Abstract][Full Text] [Related]
38. Immunogenicity and protective efficacy of tuberculosis subunit vaccines expressing PPE44 (Rv2770c).
Romano M; Rindi L; Korf H; Bonanni D; Adnet PY; Jurion F; Garzelli C; Huygen K
Vaccine; 2008 Nov; 26(48):6053-63. PubMed ID: 18822333
[TBL] [Abstract][Full Text] [Related]
39. Immunological responses and protective immunity against tuberculosis conferred by vaccination of Balb/C mice with the attenuated Mycobacterium tuberculosis (phoP) SO2 strain.
Aguilar D; Infante E; Martin C; Gormley E; Gicquel B; Hernandez Pando R
Clin Exp Immunol; 2007 Feb; 147(2):330-8. PubMed ID: 17223975
[TBL] [Abstract][Full Text] [Related]
40. A review of clinical models for the evaluation of human TB vaccines.
O'Shea MK; McShane H
Hum Vaccin Immunother; 2016 May; 12(5):1177-87. PubMed ID: 26810964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
